Trial record 2 of 3 for:    rejuvenair

Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients (Feasibility)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02483637
Recruitment Status : Active, not recruiting
First Posted : June 29, 2015
Last Update Posted : October 19, 2018
Information provided by (Responsible Party):
CSA Medical, Inc.

Brief Summary:
This study evaluates the safety of RejuvenAir Cryospray therapy to treat symptomatic chronic bronchitis patients with airflow restrictions.

Condition or disease Intervention/treatment Phase
Bronchitis, Chronic Cryotherapy Effect Device: RejuvenAir Not Applicable

Detailed Description:
Prospective, open label, single arm study with sequential accrual of subjects with known chronic bronchitis. There are two phases to this study. Phase A will enroll up to 12 subjects and will treat a single lobe to assess safety, feasibility and histology/immunology. After review of the data by the Data Safety Monitoring Board, Phase B of the study would begin. In Phase B of the study, Phase A subjects would have their remaining two lobes treated. In addition up to 24 subjects will be enrolled and will have all upper and lower lobes treated to assess safety, feasibility and immunology.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: RejuvenAir
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients
Study Start Date : February 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RejuvenAir
RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
Device: RejuvenAir
Device: RejuvenAir

Primary Outcome Measures :
  1. Adverse and Serious Adverse Events [ Time Frame: 60 days ]

Secondary Outcome Measures :
  1. Histologic appearance of bronchial biopsies in Phase A subjects [ Time Frame: 60 days ]
  2. Airway wall thickness using high resolution computed tomography (HRCT) [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females ≥40 to ≤75 years of age.
  • Subject is able to read, understand, and sign a written Informed Consent in order to participate in the study.
  • Subject agrees to continue maintenance pulmonary/COPD medications for the duration of the study.
  • Diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded.)
  • Pre-procedure post bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within 3 months of enrollment.
  • Smoking history of at least 10 pack years.
  • Non-smoking for a minimum of 6 months prior to consent and agrees to continue not smoking for the duration of the study.
  • Subject is able to adhere to and undergo 3 (4 if in Phase A) bronchoscope procedures that includes lung biopsies and multiple MCS treatments in the opinion of the investigator

Exclusion Criteria:

  • Subject has had an acute pulmonary infection or pneumonia within prior 6 weeks of study bronchoscopy.
  • Subject has had a CB and/or COPD exacerbation (requiring steroids and/or antibiotics) within 6 weeks prior to study bronchoscopy, as defined by their treating physician
  • Subject has clinically significant bronchiectasis or other respiratory disease other than chronic bronchitis and COPD.
  • Diagnosis of asthma with an onset before 30 years of age
  • Subject has bullous emphysema characterized as large bullae >30 millimeters on CT.
  • Subject has had a transplant.
  • Subject has the inability to walk >140 meters
  • Subject has PaC02 >8kPa, or a PaO2<7kPa at room air.
  • Subject has a RVSP >45mmHg or a LVEF<45% on 2D-cardiac echo.
  • Subject has undergone lung surgery: pneumonectomy, lobectomy, bullectomy, lung volume reduction surgery
  • Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation or other devices for emphysema.
  • Subject is unable to temporarily discontinue use of anticoagulant therapy:

warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal)

  • Subject is on >10 mg of prednisolone/day.
  • Subject has a serious medical condition, such as: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, hypertension, autoimmune disease or uncontrolled gastric reflux
  • Subject is pregnant, nursing, or planning to get pregnant during study duration.
  • Subject has received chemotherapy within the past 6 months or is expected to receive chemotherapy during participation in this study.
  • Subject is or has been in another clinical investigational study within 6 weeks of baseline.
  • Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).
  • Subject has been in another clinical investigational study within 6 weeks of baseline.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02483637

Canada, British Columbia
St. Paul's Hospital
Vancouver, British Columbia, Canada
University Medical Center Groningen
Groningen, Netherlands
United Kingdom
Chelsea and Westminster Hosptial/Royal Brompton Hosptial
London, United Kingdom, SW10 9NH
Sponsors and Collaborators
CSA Medical, Inc.
Study Director: Heather Nigro CSA Medical

Additional Information:
Godwin BL, Coad JE, "Healing responses following cryothermic and hyperthermic tissue ablation. " SPIE Proceedings 2009: Volume 7181, p1-9
Pulmonary Physiology, Levitzky M. 7th ed. 2007, The McGraw-Hill Companies

Responsible Party: CSA Medical, Inc. Identifier: NCT02483637     History of Changes
Other Study ID Numbers: 012
First Posted: June 29, 2015    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by CSA Medical, Inc.:
spray cryotherapy
chronic bronchitis
airflow restrictions

Additional relevant MeSH terms:
Acute Disease
Bronchitis, Chronic
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Pulmonary Disease, Chronic Obstructive